Matthew Genyeh Mei MD

Hematologic Oncology

Associate Professor

Division of Lymphoma1500 East Duarte RoadDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-389-3059

Dr. Mei is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mei's full profile Already have an account?

Summary

Dr. Matthew Mei is an oncology specialist based in Duarte, CA, currently serving as a Clinical Associate Professor at City of Hope Comprehensive Cancer Center since 2014. He completed his residency in Internal Medicine at the University of California, San Francisco, followed by a fellowship in Hematology and Medical Oncology at the Los Angeles County-Harbor-UCLA Medical Center. His expertise includes hematologic oncology, bone marrow transplantation, and Hodgkin's lymphoma. Dr. Mei has contributed to several publications in respected journals and has been involved as a principal investigator or contact in multiple clinical trials focused on lymphoma and related conditions.

Education & Training

Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2007 - 2010
Case Western Reserve University School of MedicineClass of 2007

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2009 - 2028
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Sunrise Acute Care, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017

Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
COMPLETED
PHASE2
Rituximab + Immunotherapy in Follicular Lymphoma Start of enrollment: 2018 Oct 30
TERMINATED
PHASE1
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy Start of enrollment: 2022 Jul 25
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact

Publications & Presentations

PubMed

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation.
Tamer Othman, Dongyun Yang, Geoffrey Shouse, Hoda Pourhassan, Salman Otoukesh
Transplantation and Cellular Therapy. 2026-07-10
Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort Study.
Hamza Mohammed, Muhammad Talha Waheed, Vijay Trisal, Isaac Benjamin Paz, Laleh Melstrom
Annals of Surgery. 2026-06-26
Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.
Shin Yeu Ong, Lu Chen, Jomel Meeko Manzano, Reid Merryman, Harsh Shah
Blood Cancer Journal. 2026-06-25

Abstracts/Posters

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged _60 YearsClinically Relevant Abstract
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

City of Hope Doctors Present New Research on Cancer ImmunotherapiesNovember 4th, 2021
City of Hope Doctors Present Research on New Immunotherapies at American Society of Hematology ConferenceDecember 9th, 2019
Rituximab Key to Survival After Transplant for Mantle Cell LymphomaNovember 16th, 2017